Retatrutide vs Tirzepatide vs Semaglutide: what the research actually shows
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
Retatrutide, tirzepatide, and semaglutide are three of the most-studied peptides in modern metabolic research. They're discussed together because each acts on incretin-related receptor pathways · but they differ in how many pathways they engage and in how mature their evidence base is.
| Peptide | Receptors | Research stage |
|---|---|---|
| Semaglutide | GLP-1 | Extensively published |
| Tirzepatide | GLP-1 + GIP | Extensively published |
| Retatrutide | GLP-1 + GIP + glucagon | Emerging / earlier-phase |
The mechanism: incretin receptor agonism
All three are built around incretin signaling · pathways researchers study for glucose handling, appetite signaling, and energy metabolism. The key difference is how many receptor pathways each engages: one (semaglutide), two (tirzepatide), or three (retatrutide).
What the research community anecdotally discusses
Beyond the formal literature, research and self-experimentation communities share anecdotal observations comparing these peptides. These are unverified anecdotal reports, not controlled findings, and BioRegen does not make or endorse any claims based on them.
Selected research references
- Jastreboff AM, et al. (2023). Retatrutide for Obesity · A Phase 2 Trial. N Engl J Med. doi:10.1056/NEJMoa2301972
- Rosenstock J, et al. (2021). Tirzepatide (SURPASS-1). Lancet. doi:10.1016/S0140-6736(21)01324-6
Reference metadata sourced via PubMed.